SGN-CD33A

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Promyelocytic Leukemia

Phase 1

A Safety Study of SGN-CD33A in AML Patients

CompletedNCT01902329

Seagen Inc.Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia

Start: 2013-07-31End: 2017-12-08Updated: 2018-01-05

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

CompletedNCT02326584

Seagen Inc.Acute Myelogenous Leukemia, Acute Myeloid Leukemia

Start: 2014-12-31End: 2018-04-10Updated: 2018-05-09

Related Papers

CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics

Blood2018-11-29

Targeted Chemotherapy vs. Immuno-Based Therapies in AML

Oncology Times2018-11-14

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

2018-07-2546 citations

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Blood2017-12-01177 citations

Abstract CT120: Assessment of myeloblast CD33 receptor occupancy (RO) by vadastuximab talirine in patients with acute myeloid leukemia (AML) receiving monotherapy treatment

Cancer Research2017-07-011 citations

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Blood2016-12-0243 citations

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Blood2016-12-0229 citations

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood2016-12-0229 citations

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Blood2016-12-025 citations

SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML)

Biology of Blood and Marrow Transplantation2016-02-184 citations

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Blood2015-12-0329 citations

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Blood2015-12-0324 citations

Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)

Cancer Research2015-08-016 citations

Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Blood2014-12-0634 citations